CUE (Cue Biopharma) Tariff Resilience Score: 7/10 (As of Jul. 03, 2026)


CUE Cue Biopharma Inc CUE
59 GF Score
Price $28.33
GF Value $62.36
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Cue Biopharma Tariff Resilience Score?

Cue Biopharma CUE -0.28% 59 Tariff Resilience Score is 7 as of Jul. 03, 2026. GuruFocus rates CUE with a GF Score™ of 59/100 and a GF Value™ of $62.36 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,373 Biotechnology companies, Cue Biopharma ranks better than 90.39% on this metric.

Cue Biopharma has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Cue Biopharma has Biopharma industry generally has exemptions, but supply chain for raw materials could be affected. Strong R&D focus and partnerships provide some resilience against tariff impacts.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Cue Biopharma might have Highly Resilient.

Cue Biopharma  (NAS:CUE) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Cue Biopharma Tariff Resilience Score Related Terms

CUE vs ALPS, AARD, KLRS: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Cue Biopharma's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cue Biopharma Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cue Biopharma's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Cue Biopharma's Tariff Resilience Score falls into.


CUE
59GF Score
Cue Biopharma Inc CUE
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Cue Biopharma (CUE) has a Tariff Resilience Score of 7 as of Jul. 03, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Cue Biopharma ranks #132 out of 1373 companies in the Biotechnology industry, placing it in the top 9.6%.
Is Cue Biopharma's Tariff Resilience Score too high?
Cue Biopharma's current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. Cue Biopharma's value of 7 is 75% above this industry median. Based on the distribution chart, Cue Biopharma ranks #132 out of 1373 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Cue Biopharma has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cue Biopharma's Tariff Resilience Score compare to ALPS and AARD?
According to the Biotechnology industry distribution chart, Cue Biopharma ranks #132 out of 1373 companies for Tariff Resilience Score. This places Cue Biopharma in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Cue Biopharma's value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,373 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cue Biopharma's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cue Biopharma's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cue Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cue Biopharma (CUE) is currently considered Possible Value Trap. The stock's GF Value™ is $62.36, compared to a current price of $28.33 — trading 54.6% below its estimated fair value. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. Cue Biopharma's overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Cue Biopharma (CUE), the current Tariff Resilience Score is 7 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cue Biopharma (CUE) Overvalued in 2026?

Based on GuruFocus' analysis, Cue Biopharma stock appears to be undervalued. The current stock price of $28.33 is trading 54.6% below its estimated GF Value™ of $62.36. GuruFocus considers Cue Biopharma to be Possible Value Trap.

Key valuation signals for CUE:

  • Tariff Resilience Score: 7
  • GF Value™: $62.36 vs. price of $28.33 (54.6% below fair value)
  • GF Score™: 59/100 with 3 warning signs
  • Industry Position: 75% above the Biotechnology median (#132 of 1373)

No single metric tells the full story. See the CUE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cue Biopharma Business Description

Other Exchanges 1UC0:Germany
Address 40 Guest Street, Boston, MA, USA, 02135
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
59GF Score

Get the complete analysis for CUE

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.33
Price
$62.36
GF Value